Insider Trading April 2, 2026

Pale Fire Capital Acquires $10.4M in Phreesia Stock as Shares Hover Near 52-Week Low

Institutional buying by Pale Fire Capital coincides with mixed analyst reactions after Phreesia lowers fiscal 2027 revenue outlook

By Sofia Navarro PHR
Pale Fire Capital Acquires $10.4M in Phreesia Stock as Shares Hover Near 52-Week Low
PHR

Pale Fire Capital SE and related entities purchased a total of $10.4 million of Phreesia, Inc. (PHR) common shares across transactions executed March 31 through April 2, 2026. The acquisitions raise Pale Fire Capital SICAV a.s.'s direct stake to 8,924,329 shares. The activity takes place while Phreesia shares trade close to their 52-week low and following the company27s mixed fourth-quarter fiscal 2026 results and a trimmed fiscal 2027 revenue forecast that prompted several analyst price-target adjustments.

Key Points

  • Pale Fire Capital SE and related entities purchased Phreesia common stock in transactions coded "P" totaling $10.4 million between March 31 and April 2, 2026, lifting Pale Fire Capital SICAV a.s.'s direct holdings to 8,924,329 shares.
  • Phreesia reported stronger-than-expected fourth-quarter fiscal 2026 results with non-GAAP EPS of $0.33 and adjusted EBITDA of $29.4 million, but cut fiscal 2027 revenue guidance by about 7% due to lower pharmaceutical advertising commitments.
  • Analyst reactions varied: BMO Capital, DA Davidson, Piper Sandler, and KeyBanc adjusted price targets and ratings in response to the guidance change, highlighting mixed market sentiment for the healthcare technology stock.

Pale Fire Capital SE, together with affiliated entities, reported a series of purchases of Phreesia, Inc. (NASDAQ: PHR) common stock that collectively amount to $10.4 million. All of the reported purchases were annotated with transaction code "P".

The transactions were carried out over three days from March 31, 2026 through April 2, 2026. On March 31, 2026, the firm acquired 1,000,500 shares at prices ranging from $7.7780 to $8.3039. On April 1, 2026, an additional 168,764 shares were bought at prices between $8.4080 and $8.5269. The activity concluded on April 2, 2026 with the purchase of 106,236 shares at $8.3061.

Following the completion of these trades, Pale Fire Capital SICAV a.s. directly holds 8,924,329 shares of Phreesia. Entities and individuals that may be deemed to beneficially own these positions include Pale Fire Capital SE, Pale Fire Capital investicni spolecnost a.s., Dusan Senkypl, and Jan Barta.


Market context for the purchases is notable. Phreesia shares have been under pressure, trading near a 52-week low of $7.77 and down 68% over the past 12 months. According to InvestingPro analysis, the stock appears undervalued at current levels, with the platform identifying 15 additional ProTips for investors assessing the healthcare technology company.

The insider buying arrives in the wake of Phreesia27s reported fourth-quarter fiscal 2026 results, which topped consensus on several metrics. The company posted non-GAAP earnings per share of $0.33, above the consensus estimate of $0.31. Adjusted EBITDA for the quarter was $29.4 million, exceeding the expected $28.1 million.

Despite those upside results, Phreesia trimmed its fiscal 2027 revenue guidance by approximately 7%. The company attributed the reduction to lower advertising spend commitments from pharmaceutical clients, a factor it cited directly when adjusting outlook. In response to the revised guidance, Citizens reduced its coverage rating on the stock from Market Outperform to Market Perform.

Several sell-side firms updated price targets for Phreesia after the guidance change. BMO Capital lowered its target to $14.00 from $32.00 while keeping an Outperform rating. DA Davidson cut its target from $30.00 to $14.00 but maintained a Buy rating. Piper Sandler adjusted its target to $23 from $34, and KeyBanc reiterated an Overweight rating with an unchanged $28.00 price target. These adjusted outlooks reflect differing analyst interpretations of the revenue revision and its implications for valuation.


The reported purchases by Pale Fire Capital and the company27s recent operating and guidance updates present a mixed picture: better-than-expected near-term financial performance paired with a downgraded revenue outlook that has prompted a range of analyst responses. The details reported by Pale Fire Capital indicate a concentrated purchasing program across three trading days and raise the shareholder count for the named Pale Fire entities to a direct holding of 8,924,329 shares.

Available information in this report is limited to the stated trades, ownership figures, reported financial results, the revised revenue outlook, and subsequent analyst revisions. No additional material beyond those points is asserted here.

Risks

  • Reduced revenue outlook tied to lower advertising spend from pharmaceutical clients presents a near-term revenue risk for Phreesia and impacts the healthcare technology and pharmaceutical advertising markets.
  • Shares trading near a 52-week low and a 68% year-over-year decline raise market-risk considerations for investors in the healthcare technology and public markets.
  • Analyst downgrades and material cuts to price targets introduce valuation uncertainty and could influence investor sentiment in the financial services sector covering technology and healthcare names.

More from Insider Trading

Tango Therapeutics R&D Head Executes $572k Share Sale Under Prearranged Plan Apr 2, 2026 Hinge Health Executive Chairman Disposes of $1.9M in Shares; Board and Analyst Moves Add Context Apr 2, 2026 Remitly Business Chief Executes Option Exercise, Sells 10,000 Shares Under 10b5-1 Plan Apr 2, 2026 Klaviyo Director Executes $3.88M Series A Sale, Converts Series B Shares Amid Buyback and Product Push Apr 2, 2026 Southland Holdings Co-COO Purchases 29,177 Shares as Company Battles Large Loss and Litigation Settlement Apr 2, 2026